Atazanavir-Induced Hyperbilirubinemia Mechanism

Contributing Factors and Clinical Implications

• Atazanavir may also inhibit bilirubin transporters OATP1B1 and OATP1B3, further contributing to hyperbilirubinemia 1
• Atazanavir-induced hyperbilirubinemia is considered an indirect hyperbilirubinemia and is not associated with hepatocellular damage, as noted by the FDA label and the American Thoracic Society 2